[go: up one dir, main page]

MX2022006783A - Nuevos derivados de metilquinazolinona. - Google Patents

Nuevos derivados de metilquinazolinona.

Info

Publication number
MX2022006783A
MX2022006783A MX2022006783A MX2022006783A MX2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A
Authority
MX
Mexico
Prior art keywords
methylquinazolinone
derivatives
new
compound
formula
Prior art date
Application number
MX2022006783A
Other languages
English (en)
Inventor
Daniel Hunziker
Juergen Wichmann
Cosimo Dolente
David Stephen Hewings
Daniela Krummenacher
Piergiorgio Francesco Tommaso Pettazzoni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022006783A publication Critical patent/MX2022006783A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Combines (AREA)
  • Harvester Elements (AREA)

Abstract

La invención proporciona un compuesto novedoso que tiene la Fórmula general (I) (ver Fórmula) (I), o una sal farmacéuticamente aceptable de este. El compuesto de Fórmula (I) se puede utilizar como medicamento.
MX2022006783A 2019-12-10 2020-12-08 Nuevos derivados de metilquinazolinona. MX2022006783A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10
PCT/EP2020/084976 WO2021116055A1 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Publications (1)

Publication Number Publication Date
MX2022006783A true MX2022006783A (es) 2022-07-11

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006783A MX2022006783A (es) 2019-12-10 2020-12-08 Nuevos derivados de metilquinazolinona.

Country Status (29)

Country Link
US (2) US12116349B2 (es)
EP (2) EP4483882A3 (es)
JP (2) JP7108146B2 (es)
KR (1) KR102836833B1 (es)
CN (2) CN118791472A (es)
AR (1) AR122351A1 (es)
AU (1) AU2020403443B2 (es)
CL (1) CL2022001529A1 (es)
CO (1) CO2022008968A2 (es)
CR (1) CR20220251A (es)
DK (1) DK4073065T3 (es)
ES (1) ES3023264T3 (es)
FI (1) FI4073065T3 (es)
HR (1) HRP20250418T1 (es)
HU (1) HUE071148T2 (es)
IL (2) IL292161B2 (es)
LT (1) LT4073065T (es)
MA (1) MA58087B1 (es)
MX (1) MX2022006783A (es)
PE (1) PE20221778A1 (es)
PH (1) PH12022551119A1 (es)
PL (1) PL4073065T3 (es)
PT (1) PT4073065T (es)
RS (1) RS66721B1 (es)
SI (1) SI4073065T1 (es)
TW (1) TWI877268B (es)
UA (1) UA128299C2 (es)
WO (1) WO2021116055A1 (es)
ZA (2) ZA202204675B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221027A1 (es) * 2019-12-10 2022-06-16 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
PT4073065T (pt) * 2019-12-10 2025-04-15 Hoffmann La Roche Novos derivados de metilquinazolinona
KR102904179B1 (ko) 2020-06-09 2025-12-26 어레이 바이오파마 인크. Braf-관련 질환 및 장애의 치료를 위한 4-옥소-3,4-다이하이드로퀸아졸린온 화합물
IL308748A (en) 2021-06-08 2024-01-01 C4 Therapeutics Inc Therapeutic agents for knockdown of mutant BRAF
KR102699226B1 (ko) * 2021-06-09 2024-08-27 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
MX2023014563A (es) * 2021-06-09 2024-02-08 Hoffmann La Roche Combinacion de un inhibidor de braf particular (interruptor de paradoja) y un antagonista de union al eje de pd-1 para su uso en el tratamiento de cancer.
CA3222612A1 (en) * 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
AU2022320304A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240105382A (ko) 2021-11-04 2024-07-05 에프. 호프만-라 로슈 아게 암 치료를 위한 퀴나졸리논 화합물의 신규한 용도
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
EP4618994A1 (en) 2022-11-18 2025-09-24 F. Hoffmann-La Roche AG Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
JP2025541200A (ja) * 2022-12-15 2025-12-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん処置のための併用療法
AR131372A1 (es) * 2022-12-15 2025-03-12 Hoffmann La Roche Procedimiento para la preparación de un derivado de quinazolinona
WO2025008313A1 (en) 2023-07-04 2025-01-09 F. Hoffmann-La Roche Ag New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]- 3-fluoro-pyrrolidine-1-sulfonamide
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
WO2025153057A1 (zh) * 2024-01-17 2025-07-24 海思科医药集团股份有限公司 一种含braf抑制剂的药物组合物及其在医药上的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG10201608813PA (en) 2008-03-17 2016-12-29 Ambit Biosciences Corp Quinazoline derivatives as raf kinase modulators and methods of use thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
BR112015005982A2 (pt) 2012-09-19 2017-07-04 Novartis Ag di-hidropirrolidino-pirimidinas como inibidores de quinase
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
CN113893253A (zh) 2015-05-22 2022-01-07 普莱希科公司 用于治疗braf-v600相关的疾病的plx-8394或plx-7904
RU2724345C2 (ru) 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
TWI748317B (zh) 2019-01-03 2021-12-01 美商建南德克公司 吡啶并－嘧啶酮與喋啶酮化合物及使用方法
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
PE20221027A1 (es) 2019-12-10 2022-06-16 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
PT4073065T (pt) 2019-12-10 2025-04-15 Hoffmann La Roche Novos derivados de metilquinazolinona
KR102904179B1 (ko) 2020-06-09 2025-12-26 어레이 바이오파마 인크. Braf-관련 질환 및 장애의 치료를 위한 4-옥소-3,4-다이하이드로퀸아졸린온 화합물
JP2023554062A (ja) 2020-12-18 2023-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規アリール－ピリド－ピリミジン－オン誘導体
CN116601147A (zh) 2020-12-18 2023-08-15 豪夫迈·罗氏有限公司 新喹唑啉酮衍生物
IL308748A (en) 2021-06-08 2024-01-01 C4 Therapeutics Inc Therapeutic agents for knockdown of mutant BRAF
AU2022403854B2 (en) 2021-12-08 2025-04-17 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide

Also Published As

Publication number Publication date
KR102836833B1 (ko) 2025-07-22
CO2022008968A2 (es) 2022-07-19
CL2022001529A1 (es) 2023-02-10
DK4073065T3 (da) 2025-04-22
ZA202204675B (en) 2022-12-21
TWI877268B (zh) 2025-03-21
WO2021116055A1 (en) 2021-06-17
EP4073065B1 (en) 2025-02-19
RS66721B1 (sr) 2025-05-30
US20240174621A1 (en) 2024-05-30
NZ787393A (en) 2025-07-25
CN114787156A (zh) 2022-07-22
PE20221778A1 (es) 2022-11-16
JP2022531609A (ja) 2022-07-07
IL316473A (en) 2024-12-01
US12116349B2 (en) 2024-10-15
SI4073065T1 (sl) 2025-06-30
KR20220110554A (ko) 2022-08-08
JP7108146B2 (ja) 2022-07-27
EP4483882A3 (en) 2025-03-05
MA58087B1 (fr) 2025-04-30
IL292161B2 (en) 2025-04-01
LT4073065T (lt) 2025-04-25
PH12022551119A1 (en) 2023-08-23
CR20220251A (es) 2022-07-11
CN118791472A (zh) 2024-10-18
AU2020403443A1 (en) 2022-05-12
HUE071148T2 (hu) 2025-08-28
IL292161A (en) 2022-06-01
ZA202206923B (en) 2024-10-30
CN114787156B (zh) 2024-07-26
IL292161B1 (en) 2024-12-01
AU2020403443B2 (en) 2023-02-23
PL4073065T3 (pl) 2025-05-19
UA128299C2 (uk) 2024-05-29
ES3023264T3 (en) 2025-05-30
BR112022011123A2 (pt) 2022-08-23
TW202504895A (zh) 2025-02-01
PT4073065T (pt) 2025-04-15
HRP20250418T1 (hr) 2025-06-06
AR122351A1 (es) 2022-09-07
CA3162883A1 (en) 2021-06-17
TW202136245A (zh) 2021-10-01
US20220298119A1 (en) 2022-09-22
JP7802514B2 (ja) 2026-01-20
JP2022124458A (ja) 2022-08-25
EP4483882A2 (en) 2025-01-01
FI4073065T3 (fi) 2025-04-16
EP4073065A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
PH12020500673A1 (en) Compounds
EA202193015A1 (ru) Ингибиторы cdk
SA521422143B1 (ar) 15-pgdh مثبط
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
MX2016014939A (es) Derivados de carboxamida.
BR112018074985A2 (pt) composições antibacterianas
MX383577B (es) Derivados sustituidos de guanidina.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12022551241A1 (en) Egfr inhibitors
PH12021552953A1 (en) Tricyclic compounds
MY193239A (en) Novel b-lactamase inhibitors
MX379576B (es) Derivados de azetidina
MX2022006776A (es) Composiciones farmaceuticas oftalmicas.
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
EA202190458A1 (ru) Составы, содержащие дендример
MY208423A (en) Composition of aminopyran derivative